- Improved profitability across each business segment - Future strategic direction now clearly defined FEBRUARY 13, 2026 © Kirin Holdings Company, Limited Implementation of Strategic Path (KV2027) Clearly on Track KV2027 REVIEW Blackmores and FANCL acquisitions solidified Health Science as our third growth engine Kirin Group Long-Term Vision Our Vision for 2035 and a Clear Path towards Maximizing Corporate Value ENVIRONMENTAL OUTLOOK Preparing for Structural Shifts We will operate our business based on the ...

Core Viewpoint - The article discusses the recent approval of Eli Lilly's new drug eloralintide for clinical trials in China, aimed at treating obesity and related conditions, highlighting the competitive landscape in the GLP-1 drug market [4][6]. Group 1: Drug Approval and Clinical Trials - Eli Lilly's eloralintide injection has received clinical trial approval from China's National Medical Products Administration (NMPA) for treating obesity or overweight individuals with knee osteoarthritis pain [4]. - The company is advancing multiple Phase III clinical studies for eloralintide, targeting obesity, obstructive sleep apnea, and knee osteoarthritis, indicating a significant step in local research [6]. Group 2: Market Competition and Differentiation Strategies - The competition in the domestic semaglutide market is intensifying, with several biosimilars for type 2 diabetes and obesity either in Phase III trials or having received IND approval [6]. - In response to increasing "homogenization" pressure, companies are accelerating the search for differentiation strategies, including the development of oral formulations, extending half-lives, multi-target approaches to enhance efficacy, and exploring new sales and service models [8].

Core Viewpoint - The article discusses Tencent's strategic investments in the GLP-1 weight loss drug sector, emphasizing a long-term vision that integrates health management, data processing, and service connectivity rather than focusing solely on individual drug performance [4][11]. Investment Strategy - Tencent's investment approach is structured in three phases: 1. Initial investments in near-commercial GLP-1 assets to secure stable cash flow from chronic disease management [6]. 2. Betting on next-generation technologies targeting multiple metabolic pathways to enhance weight loss effectiveness [6]. 3. Diversifying into various technological approaches to mitigate risks associated with GLP-1 competition [8]. Market Dynamics - The weight loss drug market is characterized by a large and growing user base, with significant potential for ongoing service engagement across multiple health management areas [9]. - There is a strong willingness to pay for weight loss solutions, transitioning from high-cost, niche markets to broader accessibility through various payment structures [10]. - Weight management is interconnected with chronic diseases, allowing for an expanded service offering that includes diagnostics, medication, and follow-up care [10]. Infrastructure Development - Tencent is not only investing in equity but also building foundational infrastructure through health-related patents, focusing on improving measurement accuracy and data integration for chronic disease management [12]. - Recent patent applications include innovations in GLP-1 receptor activation, aiming to create more effective and cost-efficient treatments [13][15]. Risk and Opportunity Assessment - Tencent's investments in companies like Xianweida and Minwei Biotech reflect a balanced risk preference, combining stable assets with high-potential, flexible opportunities in the next-generation drug space [16]. - The strategy aims to create a sustainable business model in weight management, leveraging technology and service integration to enhance commercial efficiency [17].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged misleading statements regarding the efficacy of its drug setrusumab, impacting investors who purchased shares between August 3, 2023, and December 26, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx made false statements about setrusumab's ability to reduce fracture rates despite increasing bone density, which misled investors [5]. - Investors who purchased shares during the specified period may be eligible for compensation without incurring out-of-pocket costs through a contingency fee arrangement [2]. Group 2: Participation Information - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by April 6, 2026, to represent the class in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking highly in the industry since 2013 [4].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged misleading statements regarding the potential of setrusumab and its study protocols, impacting investors who purchased stock between August 3, 2023, and December 26, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx made false and/or misleading statements about setrusumab's ability to increase bone density and its correlation with fracture rates, which were misrepresented to investors [5]. - Investors who purchased common stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by April 6, 2026, to represent the class in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Fanapt revenue growth of 24% was primarily driven by a 149% surge in new-to-brand prescriptions following the bipolar disorder commercial launch. Management attributes accelerating Fanapt momentum to targeted commercial investments, including direct-to-consumer campaigns and a sales force expansion to approximately 300 representatives. HETLIOZ revenue declined 7% due to generic competition, though the product has retained the majority of market share after three years of generic entry. The approval ...

Core Insights - Vertex Pharmaceuticals reported a revenue of $3.19 billion for the quarter ended December 2025, reflecting a year-over-year increase of 9.6% and surpassing the Zacks Consensus Estimate of $3.17 billion by 0.7% [1] - The earnings per share (EPS) for the quarter was $5.03, an increase from $3.98 in the same quarter last year, although it fell short of the consensus estimate of $5.07 by 0.74% [1] Revenue Breakdown - Total product revenues were $3.19 billion, exceeding the average estimate of $3.16 billion from eight analysts [4] - Revenue from ALYFTREK was reported at $380.1 million, surpassing the average estimate of $367.1 million from six analysts [4] - Revenue from Trikafta/Kaftrio was $2.57 billion, matching the average estimate from six analysts, but showing a year-over-year decline of 5.5% [4] - Other product revenues reached $237.4 million, exceeding the estimated $216.84 million and representing a year-over-year increase of 24.2% [4] Stock Performance - Over the past month, Vertex shares have returned +2.6%, while the Zacks S&P 500 composite experienced a -0.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Picard Medical, Inc. of Class Action Lawsuit and Upcoming Deadlines - PMI [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Picard Medical, Inc. ("Picard" or the "Company") (NYSE: PMI). Such investors are advised to contact Danielle Peyton at [[email protected]] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 798 ...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [[email protected]] or 646-581-9980, (or 888.4- ...

Approval will broaden the NARCAN® Nasal Spray portfolio, and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new multipack configurations of over-the-counter (OTC) NARCAN® Nasal Spray. This approval expands the NARCAN® Nasal Spray p ...